Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of 17.33 billion. The enterprise value is 14.55 billion.
| Market Cap | 17.33B |
| Enterprise Value | 14.55B |
Important Dates
The next estimated earnings date is Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 61.55M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.37% |
| Shares Change (QoQ) | -3.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 60.84M |
Valuation Ratios
The trailing PE ratio is 12.64 and the forward PE ratio is 15.36.
| PE Ratio | 12.64 |
| Forward PE | 15.36 |
| PS Ratio | 4.75 |
| PB Ratio | 3.27 |
| P/TBV Ratio | 5.42 |
| P/FCF Ratio | 15.88 |
| P/OCF Ratio | 15.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.74, with an EV/FCF ratio of 13.34.
| EV / Earnings | 10.62 |
| EV / Sales | 3.96 |
| EV / EBITDA | 10.74 |
| EV / EBIT | 11.33 |
| EV / FCF | 13.34 |
Financial Position
The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.22 |
| Quick Ratio | 6.20 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | 0.14 |
| Interest Coverage | 49.22 |
Financial Efficiency
Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 15.86%.
| Return on Equity (ROE) | 28.12% |
| Return on Assets (ROA) | 13.26% |
| Return on Invested Capital (ROIC) | 15.86% |
| Return on Capital Employed (ROCE) | 21.84% |
| Revenue Per Employee | 1.38M |
| Profits Per Employee | 519,476 |
| Employee Count | 2,682 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 21.91 |
Taxes
In the past 12 months, Genmab has paid 182.81 million in taxes.
| Income Tax | 182.81M |
| Effective Tax Rate | 11.77% |
Stock Price Statistics
The stock price has increased by +9.73% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +9.73% |
| 50-Day Moving Average | 233.33 |
| 200-Day Moving Average | 213.31 |
| Relative Strength Index (RSI) | 90.64 |
| Average Volume (20 Days) | 272 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of 3.65 billion and earned 1.37 billion in profits. Earnings per share was 21.62.
| Revenue | 3.65B |
| Gross Profit | 3.45B |
| Operating Income | 1.27B |
| Pretax Income | 1.55B |
| Net Income | 1.37B |
| EBITDA | 1.33B |
| EBIT | 1.27B |
| Earnings Per Share (EPS) | 21.62 |
Balance Sheet
The company has 2.90 billion in cash and 148.00 million in debt, giving a net cash position of 2.75 billion.
| Cash & Cash Equivalents | 2.90B |
| Total Debt | 148.00M |
| Net Cash | 2.75B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.30B |
| Book Value Per Share | 86.21 |
| Working Capital | 3.28B |
Cash Flow
In the last 12 months, operating cash flow was 1.13 billion and capital expenditures -43.44 million, giving a free cash flow of 1.09 billion.
| Operating Cash Flow | 1.13B |
| Capital Expenditures | -43.44M |
| Free Cash Flow | 1.09B |
| FCF Per Share | n/a |
Margins
Gross margin is 94.54%, with operating and profit margins of 34.95% and 37.59%.
| Gross Margin | 94.54% |
| Operating Margin | 34.95% |
| Pretax Margin | 42.60% |
| Profit Margin | 37.59% |
| EBITDA Margin | 36.40% |
| EBIT Margin | 34.95% |
| FCF Margin | 29.91% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.37% |
| Shareholder Yield | n/a |
| Earnings Yield | 7.91% |
| FCF Yield | 6.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 9.99 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.99 |
| Piotroski F-Score | 5 |